CAMRA All Hands Meeting Project III - Dose Response Charles Haas -- Drexel Carole Bolin -- MSU.

Slides:



Advertisements
Similar presentations
Responding to the Threat of Bioterrorism: A Status Report on Vaccine Research in the United States Good Morning. Over the next 1 ½ hours of so I’ll be.
Advertisements

1 U.S. EPA and DHS Center of Excellence CAMRA is an interdisciplinary research center established to develop scientific knowledge on the fate and risk.
Prepared by Dr Alissar Rady, WHO Lebanon
CHAPTER 27 Animal-Transmitted, Arthropod- Transmitted, and Soilborne Microbial Diseases.
Bioterrorist Agents: Tularemia
Animal Model PK/PD: A Tool for Drug Development
Communicable Diseases. Figure 2.10: The Burden of Disease by Group of Cause, Percent of Deaths, 2001 Data from Lopez AD, et al Global Burden of Disease.
DUAL USE RESEARCH OF CONCERN US Government (USG) Policy for Institutional Oversight of Life Sciences 10/13/2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2009.
THE BLACK PLAGUE. The Italian writer Boccaccio said the Plague’s victims often… "ate lunch with their friends and dinner with their ancestors in paradise."
1 CIPROFLOXACIN FOR PROPHYLAXIS OF CLINICAL DISEASE DUE TO INHALED B. anthracis.
Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,
Prevention and control of communicable disease. Over the last century, infectious diseases have lost a lot of their threat to individuals’ health as well.
New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research.
Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings PowerPoint ® Lecture Slide Presentation prepared by Christine L. Case Microbiology.
What will be studied? What are the risks? Part II October 1, 2007 National Emerging Infectious Diseases Laboratories.
HUMAN HEALTH & ENVIRONMENTAL RISKS
Pandemic Influenza Preparedness Kentucky Department for Public Health Department for Public Health.
Anthrax Vaccine Protocol Jairam Lingappa, MD Meningitis & Special Pathogens Branch, Division of Bacterial and Mycotic Diseases, NCID, CDC Speaker 2 of.
CBER Perspective VRBPAC Meeting, November 16, 2010.
Bioterrorism MLAB 2434: Microiology Keri Brophy-Martinez.
US biosafety experiences during the last two decades: Lessons and achievements PETER PALESE MOUNT SINAI SCHOOL OF MEDICINE, New York BIOSECURITY, ISTANBUL,
Pandemic Influenza; A Harbinger of Things to Come Michael T Osterholm PhD, MPH Director, Center for Infectious Disease Research and Policy Associate Director,
Local Emergency Response to Biohazardous Incidents Dr. Elizabeth Whalen, MD Medical Director Albany County Health Department April 8, 2005 Northeast Biological.
SHAHID ALI Ph.D Scholar (Botany) 08-arid-954
Influenza: Pathogenesis Overview ● Entry Route ● Infection Cycle ● Virulence ● Clinical Course ● Complications ● Factors.
Phylogenetic relationship of lentiviruses. - The heterologous host all develop disease that show many parallels to human AIDS, the similarities including.
Biological Attack Model (BAM) Status Update February 22 Richard Bornhorst Robert Grillo Deepak Janardhanan Shubh Krishna Kathryn Poole.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Environmental Hazards and Human Health Chapter 17.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2012.
1 Novel Influenza A H1N1 Outbreak: The Florida Response Epidemiology Perspective: Situation Update.
SMALL POX By: Harrison Keyes. WHAT Small pox, know as Variola Major and Variola Minor to the latins. Small pox can be found in small blood vessels of.
Rationale for Additional Post-Exposure Prophylaxis Options Bradley A. Perkins, M.D. Meningitis & Special Pathogens Branch, Division of Bacterial and Mycotic.
John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group One: Influenza Virulence and Antigenic.
Preclinical evaluation of safety, efficacy, immunogenicity of a recombinant rBCG Pasteur B vaccine Group B4 March 16, 2011 Adane Miheret, Tewodros Tariku.
1 EPIDEMIOLOGY 200B Methods II – Prediction and Validity Scott P. Layne, MD.
Influenza biology and epidemiology. The course of illness  Symptoms  Fever, headache, body aches, fatigue  Cough, sore throat, runny nose  Duration:
INFECTIOUS DISEASE EPIDEMIOLOGY Instructors: Iman Ramadan, MD King Abdulaziz University Mary C. Smith Fawzi, ScD Harvard University.
Using Models to Assess Microbial Risk: A Case Study CAMRA August 10 th, 2006.
By Dr. Victoria J. Cabrera DVM.  Is a lethal encephalitis cause by a virus in the family Rhabdoviridae genus Lyssavirus  Exposure occurs through the.
Robert Gay, ACVCSD.  Pierce through the skin to obtain blood meals  Feed from one host to another host without discrimination.
INFLUENZA LUKE UYEMURA ENGLISH 100 ESP. BASIC INFO Definition: Influenza, more commonly know as the flu, is a viral infection that attacks your respiratory.
Cervical Cancer. Female Gynecologic Cancers Cervical Cancer.
Smallpox vaccine in combination with ST-246 Robert Jordan, Ph.D. SIGA Technologies, Inc FDA – Public HearingMay 17, 2007.
Infection and Disease Fungi Parasites Nosocomial infection Diagnosis of infectious disease.
Medical Countermeasure Systems (MCS)
CHLAMYDIA, RICKETTSIA AND MYCOPLASMA.
Antimicrobial vaccines List the main types of immunization List the main types of vaccines Describe the advantages and disadvantages of different types.
Knowledge Management Approach for CAMRA Community Rosina Weber College of Information Science & Technology Drexel University.
Rational Strategies Interventions of choiceInterventions of choice Economic, social and other non-medical countermeasures Interventions of last resortInterventions.
Framing a research question Chitra Grace A Scientist- C (PGDHE) NIE, Chennai RM Workshop for ICMR Scientists 01/11/2011.
LASSA FEVER- WHAT YOU NEED TO KNOW. INTRODUCTION Lassa fever is a viral hemorrhagic fever Caused by Lassa Virus First identified in Lassa town, Borno.
Diseases in Nature Conference John Herbold DVM, MPH, PhD, DACVPM, FACE Center for Biosecurity & Public Health Preparedness University of Texas School of.
Disaster Nursing. Bioterrorism and Weapons of Mass Destruction By: Brittney Mathis.
Objectives  Define risk assessment as it relates to biosafety  Understand the risk assessment process and how to implement it  Discuss risk factors.
روش استاندارد انتقال نمونه هاي عفوني براساس الزامات بين المللي.
The National Oversight of Bioscience Researches in Korea : Biosafety & Biosecurity WK Seong, CK Yoo, JK Lee, JB Ahn, and TJ Son Division of Biosafety Evaluation.
The Role of Environmental Processes in Infectious Disease Dynamics Andrew Brouwer University of Michigan.
Seasonal Influenza and Pandemic Influenza A (H1N1, H5N1) Virus Dr. Alaa kuttar musa Department of Medicine College of Medicine/ Basra University.
Chapter 11: Nursing in Pandemics and Emergency Preparedness.
Dual Use Research of Concern
Stanford University Dual Use Research of Concern in the Life Sciences
Emerging Infectious Diseases:
Transmission Pathways: Airborne Disease
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Immune System When first exposed to disease, organisms make specific antibodies to mark the foreign invaders so the white blood cells know what to destroy.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Presentation transcript:

CAMRA All Hands Meeting Project III - Dose Response Charles Haas -- Drexel Carole Bolin -- MSU

Project III Objectives Comprehensive and synoptic review, analysis and development of DR relationships for cat. A and other agents Targeted animal studies to provide dose-response data for the static and dynamic risk assessment models (MSU)

Tool Development Developed and validated fitting tool in “R” –Validation against prior data sets using MATLAB and Excel –Enables more rapid fitting in a widely available cross-platform solution

Characteristics of Available Dose-Response Data Animal studies –Hosts Primates Rodents (human as available) –Other characteristics Inbred v. outbred Endpoint: death in all data sets except one Lassa experiment Exposure Route –B. anthracis inhalation exposure –Y. pestis and Lassa: subcutaneous exposure –V. major: intraperitoneal and intracerebral exposure Nature of data sets –Number of doses between 4 and 12 –Number of subjects at each dose between 3 and 9 –Acceptable only if a data set contains at least three doses, with at least one dose at intermediate response wildfacts/factfiles/211.shtml graphic.org.uk/fat- guinea-pig.htm onder.co.uk/gerbils/images/t ateralarge.jpg1 etc.com/sqrlinfo.htm shop/london-zoo- adoptions/adopt-a- squirrel-monkey- from-london-zoo/

Suitable Data Identified for Category A Pathogens (22 data sets) Bacillus anthracis (7 data sets, all inhalation exposure) –Rhesus monkeys, Vollum strain (9 doses) –Guinea pigs, Vollum strain (6 doses) –Guinea pigs, ATCC 6605 strain (6 doses) Yersinia pestis (10 data sets, all subcutaneous exposure) –Rock squirrel, lab-reared (8 doses) and wild-caught (8 doses) –Multimammate mice 2n32 (3 doses) and 2n36 (4 doses) –Multimammate mice, caught in Transvaal (6 doses) and caught in Natal (7 doses) –Bushveld gerbils exposed to SAIMR strain (7 doses) and to SF329 strain (3 doses) –White tailed rabbits, (7 doses) –Califorinia ground squirrels, subcutaneous exposure (7 doses) Variola major (2 data sets, two exposure routes) –Suckling mice, intraperitoneal exposure (18 doses, 4 age groups) –Suckling mice, intracerebral exposure (5 doses) Lassa (3 data sets, 2 exposure routes) –Guinea pigs, inbred, subcutaneous exposure (6 doses) –Guinea pigs, outbred, subcutaneous exposure (5 doses) –Guinea pigs, outbred, aerosol exposure (4 doses) Francisella tularensis –Analysis is underway

Findings: B. anthracis, inhalation exposure, rhesus monkey and guinea pig models Refined dose-response estimate for inhalation exposure Not all data could be pooled –Pooling acceptable for data of guinea pigs exposed to different strains –Pooling acceptable for rhesus monkeys exposed to Vollum strain and guinea pigs exposed to ATCC-6605 strain Rhesus monkeys Rhesus monkeys pooled with guinea pigs exposed to ATCC 6605 strain

Findings: Y. pestis, subcutaneous exposure, various rodent models (early 20th century data) Data sets presented two behaviors –Marked response (dose-response models demonstrating goodness of fit) –Significant dispersion (no goodness of fit) –We are developing models for hyper-binomial variability No pooling of data was not possible Data for which models could be developedData exhibiting dispersion

Findings: V. major, intraperitoneal exposure, mouse model 1 Developed dose- response relation with parameters accounting for host age –Young suckling mice far more susceptible than mice only 1 to 2 days older –When trends in susceptibility with age are included, data for different age groups may be pooled 1 Marshall, R.G., and Gerone, P.J., 1960, “Susceptibility of Suckling Mice to Variola Virus,” Journal of Bacteriology, 82(1):15-19 Systematic dependency of dose response parameters to host age -- first finding of its kind

Findings: Lassa, subcutaneous and aerosol exposures, guinea pig model 1,2 Strong difference in response between inbred and outbred populations, subcutaneous exposure Pooling of subcutaneous and aerosol exposure route data possible Subcutaneous exposure, inbredSubcutaneous exposure, outbredPooled subcutaneous exposure, outbred with aerosol exposure, outbred 1 Jahrling et al., 1982, “Pathogenesis of Lass Virus Infection in Guinea Pigs,” Infection and Immunity, 37(2): Stephenson et al., 1984, “Effect of Environmental Factors on Aerosol-Induced Lassa Virus Infection,” Journal of Medical Virology, 14:

Upcoming Work Additional data acquisition –Continued literature search for dose-response data –Search for outbreak/natural exposure data for validation Other organisms –(Category B) (to be discussed) Melioidosis (Burkholderia pseudomallei) Q fever (Coxiella burnetii) Typhus fever (Rickettsia prowazekii) Viral encephalitis (alphaviruses [e.g., Venezuelan equine encephalitis, eastern equine encephalitis, western equine encephalitis]) –Influenza? ---->

Upcoming Work (con’t) Development of mechanistically-based dose-response models –Dose-time-response models tracking “body burden” –Fitting to data library Publications –Drafts in preparation Overdispersion model development (e.g. for plague) MSU experiments with F. tularensis

MSU Tularemia Experiments Study 1: –Examine three strains of F. tularensis Type A –Mouse model + oral exposure –Groups of mice given 10 8, 10 6, 10 4, 10 2 –Mice monitored at day 1, 2, 3, 4, 14 for infection and disease –Endpoint is infection not death Animals that are infected but not ill can maintain the infection May develop disease and die when antibiotic treatment stops or immunosuppressed Study 2: –Most virulent strain from Study 1 will be used –Larger groups of mice will be used to study the critical part of the dose-response curve Future? –Effect of post-exposure prophylaxis on dose-response –Effect of vaccination on dose-response

Drexel Personnel Tim Bartrand (post doc-partial) Sushil Tamrakar (doctoral) Mark Weir (doctoral, other support) Additional student being recruited Summer 2007 DHS undergrad fellows (2)